RT Journal Article
SR Electronic
T1 Psychedelic mushrooms in the USA: Knowledge, patterns of use and association with health outcomes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.20.21263824
DO 10.1101/2021.09.20.21263824
A1 R Matzopoulos
A1 R Morlock
A1 A Morlock
A1 B Lerer
A1 L Lerer
YR 2021
UL http://medrxiv.org/content/early/2021/09/22/2021.09.20.21263824.abstract
AB Introduction Popular media coverage, including of recent positive late stage clinical trials in depression and PTSD, and decriminalization initiatives, are transforming the public perception of psychedelics. However, little is known about levels of knowledge and personal use of psychedelic mushroom(s) (PM) among American adults.Methods We examined PM use and various measures of health status, quality of life and self-reported mental health outcome measures obtained through a national on-line, cross-sectional survey of adults with a demographic composition representative of the US adult population by region, gender, age, and race (weighted N = 251,297,495) from November 2020–March 2021.Results General mental health and well-being was a popular reason for PM use (63.6%). PM users were less likely to be overweight than non-users, but overall quality of life (VR-12) was lower for mental health (39.5 vs 45.5). PM users reported significantly higher levels of anxiety (GAD-7 scores of 9.6 vs 5.9) and depression (PHQ-9 scores of 11.2 vs 6.8). They were less likely to have health insurance [OR=0.50 (0.35-0.72)], but reported significantly more healthcare services utilization.Discussion and Conclusions There is a mismatch between our findings of an association between PM use and poor mental health outcomes, and current discourse on the positive health benefits of PM consumption. A significant number of Americans are already “self medicating” with PM and further research to understand the role of anecdotal knowledge and pseudoscientific information in PM uptake. There is an urgent need for a PM use-related national harm reduction strategy.Competing Interest StatementBernard Lerer and Leonard Lerer hold equity in Back of the Yard Algae Sciences and Parow Entheobiosciences. There are no other conflicts relevant to this work.Funding StatementNo external funding was received for this research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Sterling IRB in Atlanta, Georgia, reviewed the protocol (ID: 8249-RJMorlock)and determined that the study was exempt from IRB review pursuant to the terms of the U.S. Department of Health and Human Service's Policy for Protection of Human Research Subjects at 45 C.F.R. S46.104(d) and that the following exemption category applied: Category 2 Exemption (DHHS).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available prior to publication.